Discontinued — last reported Q4 '25
Ferguson Enterprises Acquisitions decreased by 52.4% to $10.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 93.3%, from $150.00M to $10.00M. Over 2 years (FY 2022 to FY 2025), Acquisitions shows a downward trend with a -32.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $162.50M | $162.50M | $162.50M | $162.50M | $12.00M | $67.00M | $118.00M | $53.00M | $22.00M | $150.00M | $92.00M | $38.00M | $21.00M | $10.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -92.6% | +458.3% | +76.1% | -55.1% | -58.5% | +581.8% | -38.7% | -58.7% | -44.7% | -52.4% |
| YoY Change | — | — | — | — | -92.6% | — | — | — | +83.3% | +123.9% | -22.0% | -28.3% | -4.5% | -93.3% |